Law360 (May 24, 2019, 4:21 PM EDT) -- A McKesson Corp. shareholder claims the drug distributor's directors benefited from a "massive insider trading binge" while participating in an industrywide conspiracy to drive up the prices of generic drugs, in a suit removed to California federal court Thursday.
Investor Jean E. Henry's derivative action heavily pulls from multidistrict litigation from state attorneys general and securities fraud class actions bringing antitrust claims against generic-drug makers who allegedly colluded to fix the pharmaceutical market.
McKesson was roped into the scrum last September, making it the first drug distributor to be linked with the alleged conspiracy by drug manufacturers like Heritage Pharmaceuticals Inc.,...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!